Immunogenicity, Efficacy, and Safety of Biosimilar Insulin Aspart (MYL-1601D) Compared with Originator Insulin Aspart (Novolog ®) in Patients with Type 1 Diabetes After 24 Weeks: A Randomized Open-Label Study

ConclusionsMYL-1601D demonstrated similar immunogenicity, efficacy, and safety profiles to Ref-InsAsp-US in patients with T1D over 24 weeks.Clinical Trial Registration ClinicalTrials.gov:NCT03760068.
Source: BioDrugs - Category: Drugs & Pharmacology Source Type: research